Viking Therapeutics Q3 net loss $24.9M; cash $930M; pipeline advances with VK2735 and VK2809

Viking Therapeutics, Inc.

2024-Q3 EPS reported -$0.69

Net loss of $24.9M ($0.22 per share) vs $22.5M loss in Q3 2023; R&D expense $22.8M.
Cash and equivalents of $930M at Sept 30, 2024, up from $362M at Dec 31, 2023.
End-of-Phase 2 meeting for subcutaneous VK2735 (obesity) planned for 4Q24; Phase 2 oral VK2735 trial expected to start 4Q24.
Positive Phase 2b VOYAGE results for VK2809 in NASH/MASH with fibrosis selected for oral presentation at AASLD Nov 19.
Positive Phase 1b results for VK0214 in X-ALD show reductions in very long-chain fatty acids and plasma lipids.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.